Blog
RSS FeedPosted by Michael Wonder on 12 Jan 2017
NICE approves kidney cancer drug for NHS use
12 January 2017 - Patients with advanced kidney cancer will have routine NHS access to the drug everolimus following recommendations by ...
Posted by Michael Wonder on 11 Jan 2017
NICE publishes final guidance on the use of Keytruda for non-small-cell lung cancer
11 January 2017 - The guidance relates to the use of Keytruda (pembrolizumab) for treating PD-L1-positive non-small-cell lung cancer in adults ...
Posted by Michael Wonder on 03 Jan 2017
The NICE year in review
3 January 2017 - NICE has reflected on some of the news over the past twelve months. ...
Posted by Michael Wonder on 03 Jan 2017
NICE says liver cancer treatment to stay within the Cancer Drugs Fund, but not recommended for routine NHS use
30 December 2016 - The drug, sorafenib tosylate (Nexavar), which is used for treating advanced hepatocellular carcinoma, is not value for ...
Posted by Michael Wonder on 31 Dec 2016
Breast cancer drug rejected for NHS use on cost-benefit grounds
29 December 2016 - Charities angered by guidance on Kadcyla, which costs £90,000 per year per patient and gives extra nine ...
Posted by Michael Wonder on 23 Dec 2016
‘Wonder’ drug for sufferers given green light for NHS use
22 December 2016 - The decision means 6,890 people in England and Wales who suffer with the debilitating inflammatory disease ...
Posted by Michael Wonder on 14 Dec 2016
NICE publishes final guidance on the use of AstraZeneca's Brilique
14 December 2016 - The guidance relates to the use of ticagrelor for the prevention of atherothrombotic events after myocardial ...
Posted by Michael Wonder on 09 Dec 2016
When the price is right: drug costing and NICE approval
5 December 2016 - Price discounts are leading to a flurry of NICE approvals. ...
Posted by Michael Wonder on 02 Dec 2016
NICE recommends new lung cancer drug pembrolizumab
2 December 2016 - Hundreds of people with advanced lung cancer will now have access to new drug pembrolizumab, also known ...
Posted by Michael Wonder on 01 Dec 2016
GSK gets green light to sell breakthrough asthma treatment to the NHS
1 December 2016 - GlaxoSmithKline has had one of its most promising new asthma drugs recommended for use on the ...
Posted by Michael Wonder on 29 Nov 2016
NICE recommends 4p a day breast cancer drug
29 November 2016 - Women with a family history of breast cancer should be offered anastrozole, not tamoxifen, says NICE ...
Posted by Michael Wonder on 25 Nov 2016
NICE reverses decision on CDF leukaemia drug after price drop
25 November 2016 - Hundreds of people could benefit as NICE decision means ibrutinib can come off the Cancer Drugs Fund ...
Posted by Michael Wonder on 23 Nov 2016
NICE publishes final guidance on the use of nivolumab for RCC
23 November 2016 - NICE has published its third final appraisal determination for nivolumab for 2016. ...
Posted by Michael Wonder on 23 Nov 2016
NICE recommends extra ‘triple therapy’ drug for treating type 2 diabetes
23 November 2016 - NICE has published final guidance recommending dapagliflozin for treating type 2 diabetes in ‘triple therapy’. ...
Posted by Michael Wonder on 23 Nov 2016
NICE reviews multiple myeloma drug and approves for routine use
23 November 2016 - Hundreds of patients set to benefit after NICE draft guidance recommends pomalidomide, a drug that treats some ...